AltStreet
EDGAR Verified
Primary Source · SEC.gov

Analytical Biotech Fund, LP

Fund Vehicle2026 vintage506(b), 3(c)(1)
Latest signalNew Form D filerForm D · 2026-03-31Last filing 2026-03-31

Raised

Pre-open

Investors

—

Min Invest

$500,000

AltStreet Analysis

·

Generated from EDGAR primary sources

Analytical Biotech Fund, LP is a Delaware limited partnership filing under Rule 506(b) and Section 3(c)(1), indicating a private hedge fund structure. The filing is pre-open with no capital raised or investor count disclosed; minimum investment is set at $500K. The fund is promoted by Syno Partners, LLC and Syno Capital, LLC, with executive officers Joseph Weilgus and Justin Xiang.

This longevity biotech fund employs a 506(b) exemption typical of manager-relationship-driven offerings that prohibit general solicitation. The $500K minimum investment sits at the lower end of institutional-grade biotech funds, which commonly require $1M+ for specialized life sciences strategies.

Data Flags

generalPre-open filing with no first sale date and no capital raised, yet minimum investment and investor eligibility parameters are fully defined
related_personsTwo separate promoter entities listed (Syno Partners, LLC and Syno Capital, LLC) with overlapping roles; unusual to declare dual promoters without clarification of respective functions

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0002108298
Entity NameAnalytical Biotech Fund, LP
ExemptionRule 506(b), Section 3(c), Section 3(c)(1)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising. Section 3(c) of the Investment Company Act of 1940: the issuer is a pooled investment vehicle relying on an exclusion from registration as an investment company. Section 3(c)(1) of the Investment Company Act: the fund is excluded from investment-company registration because it has no more than 100 beneficial owners.
Entity TypeLimited Partnership
Jurisdiction of OrganizationDelaware
Issuer Address575 Madison Avenue, Suite 1400, New York, NY 10022
Phone(646) 723-1904
Industry / Fund TypePooled Investment Fund · Hedge Fund
Investment Company ActExcluded under Section 3(c)(1) (100 beneficial owners or fewer)
Securities TypePooled Investment Fund
First Sale DateNot yet occurred (as filed)
Filing DateMarch 31, 2026
Accession Number0002108298-26-000001
Total Offering AmountIndefinite
Total Amount Sold$0 (no sales yet)
Total Investors0 (no sales yet)
Non-Accredited InvestorsNone
Minimum Investment$500,000
Offering DurationIntended to last more than one year
Sales Commissions$0
Finders' Fees$0
Net Asset Value RangeDecline to Disclose
State (Issuer Address)NY
Amendment CountOriginal filing only

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

DMarch 31, 2026

In the Terminal

Filing events

1

latest Mar 31, 2026

Critical / warning

0 / 0

0 watch · 1 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

pre_sale

Latest event New filer · Mar 31, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 1 filing event with values and deltas, latest 2026-03-31, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

n/a Syno Partners, LLC

Promoter · New York, NY

n/a Syno Capital, LLC

Promoter · New York, NY

Joseph Weilgus

Executive Officer · New York, NY

Justin Xiang

Executive Officer · New York, NY

Questions About Analytical Biotech Fund, LP

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Analytical Biotech Fund, LP?

Analytical Biotech Fund, LP is a Delaware limited partnership that filed a Form D with the SEC on March 31, 2026 as a hedge fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(1) for an offering of pooled investment fund interests. AltStreet links the issuer to Analytical Biotech Fund, LP.

Is Analytical Biotech Fund, LP legit?

AltStreet does not rate legitimacy; it reports the public record. Analytical Biotech Fund, LP filed a Form D with the SEC on March 31, 2026 claiming Rule 506(b), Section 3(c), Section 3(c)(1). A Form D is a notice of an exempt offering, not a review or approval of it. No sales had been reported as of that notice. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. The issuer is linked to Analytical Biotech Fund, LP, which AltStreet has reviewed. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Analytical Biotech Fund, LP registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Analytical Biotech Fund, LP claimed Rule 506(b), Section 3(c), Section 3(c)(1) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Analytical Biotech Fund, LP raised?

Analytical Biotech Fund, LP reported that the first sale had not yet occurred as of the Form D filed March 31, 2026, so no amount sold or investor count is on file. The total offering amount is listed as indefinite.

Who can invest in Analytical Biotech Fund, LP?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(1), it may have no more than 100 beneficial owners. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $500,000.

What is the minimum investment in Analytical Biotech Fund, LP?

The Form D lists $500,000 as the minimum investment accepted from any outside investor as of March 31, 2026. Issuers can waive their own minimums, and the figure does not include fees.

Who is selling Analytical Biotech Fund, LP and how are they paid?

The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Analytical Biotech Fund, LP?

The Form D lists 4 related persons: Syno Partners, LLC, promoter (General Partner of the Issuer); Syno Capital, LLC, promoter (Investment Manager of the Issuer); Joseph Weilgus, executive officer (Managing Member of the General Partner and Investment Manager of the Issuer); Justin Xiang, executive officer (Managing Member of the General Partner and Investment Manager of the Issuer). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Analytical Biotech Fund, LP located?

The issuer's address on its SEC filings is 575 Madison Avenue, Suite 1400, New York, NY 10022. Its phone number of record is 646-723-1904. It is organized under the laws of Delaware.

How long is the Analytical Biotech Fund, LP offering open?

The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.

How large is Analytical Biotech Fund, LP?

The issuer declined to disclose its net asset value range on the Form D, which the form permits.

Is this your offering?

Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.

Claim Profile — FreeGet Verified — $2,400/yr

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.